Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017
NEW YORK, Sept. 7, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:
Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017
http://www.reportlinker.com/p0479826/Bone-Metastases-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Discovery_and_Development
Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Summary
GlobalData, the industry analysis specialist, has released its new report, "Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global bone metastases therapeutics market. The report identifies the key trends shaping and driving the global bone metastases therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global bone metastases therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.
GlobalData estimates that the global bone metastases therapeutics market was valued at $1,425m in 2010, and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 12% over the next seven years to reach $6,390m by 2017. Although the drug pipeline for the treatment of bone metastases is strong, the launch of Amgen's Xgeva in early 2010, which is another breakthrough for bone metastases patients, is the primary driver for increased market growth. The market remains well-served with the current marketed products, most of which are significantly efficacious in their respective target areas. Essentially, the global bone metastases market is heading towards a phase of continuous growth, leveraging the current opportunities.
Scope
The report provides information on the key drivers and challenges of the bone metastases market. Its scope includes -
- Annualized global bone metastases market revenues data from 2005 to 2010, forecast for seven years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as as cathepsin K inhibitors, TGF (transforming growth factor) inhibitors, lysophosphatidic acid (LPA), G-protein-coupled receptors (GPCRs) inhibitors, integrin receptor antagonist, ATPase-dependent hydrogen ion inhibitor, Alpha-radiopharmaceutical, and a weekly oral zoledronic acid.
- Analysis of the current and future competition in the global bone metastases market. Key market players covered are Novartis AG, Amgen, F. Hoffmann-La Roche Ltd, Bayer-Algeta, Merrion Pharmaceuticals Plc., Ablynx, Genta Incorporated, Galapagos NV, Catena Pharmaceuticals, Inc, Digna Biotech, S.L., Medivir AB, and Amura Holdings.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the bone metastases therapeutics market.
- Analysis of key recent licensing and partnership agreements in bone metastases therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global bone metastases therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global bone metastases therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What's the next big thing in the global bone metastases therapeutics market landscape? – Identify, understand and capitalize.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Bone Metastasis Therapeutics: Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 8
2.3 Etiology and Pathophysiology 9
2.4 Signs and Symptoms 10
2.5 Diagnosis 11
2.6 Treatment and Management Pattern: 14
2.6.1 Systemic Therapy 14
2.6.2 External Beam Radiation Therapy 15
2.7 GlobalData Pipeline Report Guidance 16
3 Bone Metastases Therapeutics: Market Characterization 17
3.1 Bone Metastases Therapeutics Market Size (2005-2010) – Global 17
3.2 Bone Metastases Therapeutics Market Forecast (2010-2017) – Global 18
3.3 Bone Metastases Therapeutics Market Size (2005-2010) – The US 19
3.4 Bone Metastases Therapeutics Market Forecasts (2010-2017) – The US 20
3.5 Bone Metastases Therapeutics Market Size (2005-2010) – France 21
3.6 Bone Metastases Therapeutics Market Forecasts (2010-2017) – France 22
3.7 Bone Metastases Therapeutics Market Size (2005-2010) – Germany 23
3.8 Bone Metastases Therapeutics Market Forecasts (2010-2017) – Germany 24
3.9 Bone Metastases Therapeutics Market Size (2005-2010) – Italy 25
3.10 Bone Metastases Therapeutics Market Forecast (2010-2017) – Italy 26
3.11 Bone Metastases Therapeutics Market Size (2005-2010) – Spain 27
3.12 Bone Metastases Therapeutics Market Forecasts (2010-2017) – Spain 28
3.13 Bone Metastases Therapeutics Market Size (2005-2010) – The UK 29
3.14 Bone Metastases Therapeutics Market Forecasts (2010-2017) – The UK 30
3.15 Bone Metastases Therapeutics Market Size (2005-2010) – Japan 31
3.16 Bone Metastases Therapeutics Market Forecasts (2010-2017) – Japan 32
3.17 Drivers and Barriers for the Bone Metastases Therapeutics Market 33
3.17.1 Drivers for the Bone Metastases Therapeutics Market 33
3.17.2 Barriers for the Bone Metastases Therapeutics Market 33
3.18 Opportunity and Unmet Need Analysis 34
3.19 Key Takeaway 35
4 Bone Metastases Therapeutics: Competitive Assessment 36
4.1 Overview 36
4.2 Strategic Competitor Assessment 36
4.3 Product Profiles for the Major Marketed Products in the Bone Metastases Therapeutics Market 37
4.3.1 Zometa (zoledronic acid) 37
4.3.2 Xgeva (denosumab) 38
4.3.3 Bondronat (ibandronic acid) 39
4.4 Key Takeaway 39
5 Bone Metastases Therapeutics: Pipeline Assessment 40
5.1 Overview 40
5.2 Strategic Pipeline Assessment 40
5.3 Bone Metastases Therapeutics – Pipeline Analysis by Phases of Development 40
5.3.1 Bone Metastases Therapeutics – Filed Products 40
5.3.2 Bone Metastases Therapeutics – Phase III Pipeline 41
5.3.3 Bone Metastases Therapeutics – Phase II Pipeline 41
5.3.4 Bone Metastases Therapeutics – Phase I Pipeline 41
5.3.5 Bone Metastases Therapeutics – Preclinical Pipeline 41
5.3.6 Technology Trends Analytic Framework 42
5.4 Bone Metastases Therapeutics Market – Clinical Pipeline by Mechanism of Action 43
5.5 Bone Metastases Therapeutics – Promising Drugs Under Clinical Development 44
5.6 Molecule Profile for Promising Drugs Under Clinical Development 45
5.6.1 Alpharadin (radium-223 chloride) 45
5.6.2 Orazol (Zoledronic acid) 45
5.7 Key Takeaway 46
6 Bone Metastases Therapeutics: Clinical Trials Mapping 47
6.1 Clinical Trials by Country (the US, EU and Japan) 47
6.2 Clinical Trials by Phase 48
6.3 Clinical Trials by Trial Status 49
6.4 Prominent Sponsors 50
6.5 Top Companies Participating in Bone Metastases Therapeutics Clinical Trials 52
7 Bone Metastases Therapeutics: Strategic Assessment 53
7.1 Key Events Impacting the Future Market 53
7.2 Bone Metastases Therapeutics: Implications for Future Market Competition 54
8 Bone Metastases Therapeutics: Future Players 55
8.1 Introduction 55
8.2 Company Profiles 56
8.2.1 Novartis AG 56
8.2.2 Amgen Inc. 62
8.2.3 Bayer AG 65
8.2.4 Algeta ASA 69
8.2.5 Merrion Pharmaceuticals Plc 71
8.2.6 Other Companies in the Bone Metastases Therapeutics Market 72
9 Bone Metastases Therapeutics: Licensing and Partnership Deals 74
10 Bone Metastases Therapeutics: Appendix 78
10.1 Market Definitions 78
10.2 Abbreviations 78
10.3 Research Methodology 79
10.3.1 Coverage 79
10.3.2 Secondary Research 79
10.3.3 Forecasting 80
10.3.4 Primary Research 82
10.3.5 Expert Panel Validation 82
10.4 Contact Us 82
10.5 Disclaimer 82
10.6 Bibliography 83
1.1 List of Tables
Table 1: Metastatic Bone Disease is Prevalent in Many Types of Cancer 7
Table 2: Prevalence of Bone Metastases in Different Cancer Types, 2010 8
Table 3: Bone Metastases Therapeutics Market, Global, Revenue ($m), 2005–2010 17
Table 4: Bone Metastases Therapeutics Market, Global, Forecast ($m), 2010–2017 18
Table 5: Bone Metastases Therapeutics Market, France, Revenue ($m), 2005–2010 21
Table 6: Bone Metastases Therapeutics Market, France, Forecasts ($m), 2010–2017 22
Table 7: Bone Metastases Therapeutics Market, Germany, Revenue ($m), 2005–2010 23
Table 8: Bone Metastases Therapeutics Market, Germany, Forecasts ($m), 2010–2017 24
Table 9: Bone Metastases Therapeutics Market, Italy, Revenue ($m), 2005–2010 25
Table 10: Bone Metastases Therapeutics Market, Italy, Forecasts ($m), 2010–2017 26
Table 11: Bone Metastases Therapeutics Market, Spain, Revenue ($m), 2005–2010 27
Table 12: Bone Metastases Therapeutics Market, Spain, Forecasts ($m), 2010–2017 28
Table 13: Bone Metastases Therapeutics Market, The UK, Revenue ($m), 2005–2010 29
Table 14: Bone Metastases Therapeutics Market, The UK, Forecasts ($m), 2010–2017 30
Table 15: Bone Metastases Therapeutics Market, Japan, Revenue ($m), 2005–2010 31
Table 16: Bone Metastases Therapeutics Market, Japan, Forecasts ($m), 2010–2017 32
Table 17: Bone Metastases Therapeutics – Filed Products, 2010 40
Table 18: Bone Metastases Therapeutics – Phase III Pipeline, 2010 41
Table 19: Bone Metastases Therapeutics – Phase II Pipeline, 2010 41
Table 20: Bone Metastases Therapeutics – Phase I Pipeline, 2010 41
Table 21: Bone Metastases Therapeutics – Preclinical Pipeline, 2010 41
Table 22: Bone Metastases Therapeutics – Most Promising Drugs Under Clinical Development, 2010 44
Table 23: Bone Metastases Therapeutics – Clinical Trials by Country, 2011 47
Table 24: Bone Metastases Therapeutics - Clinical Trials by Phase, 2011 48
Table 25: Bone Metastases Therapeutics - Clinical Trials by Status, 2011 49
Table 26: Bone Metastases Therapeutics - Clinical Trials by Prominent Sponsors, 2011 51
Table 27: Bone Metastases Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 52
Table 28: Novartis – Oncology Pipeline, 2010 58
Table 29: Novartis Deals, 2009-2010 59
Table 30: Amgen Inc. – Oncology, Pipeline, 2010 63
Table 31: Amgen Inc. – Bone Metastases, Pipeline, 2010 63
Table 32: Amgen Inc. Deals, 2009-2010 64
Table 33: Bayer AG – Oncology Pipeline, 2010 66
Table 34: Bayer AG Deals, 2009-2010 67
Table 35: Algeta ASA Pharmaceuticals – Oncology, Pipeline, 2010 70
Table 36: Algeta ASA Pharmaceuticals – Bone Metastases, Pipeline, 2010 70
Table 37: Algeta ASA Deals, 2009-2010 70
Table 38: Merrion Pharmaceuticals – Oncology Pipeline, 2010 71
Table 39: Merrion Pharmaceuticals – Oncology Pipeline, 2010 71
Table 40: Merrion AG Deals, 2009-2010 72
Table 41: Bone Metastases Pain Therapeutics Market – Future Players 72
Table 42: Bone Metastases Therapeutics, Global, Deals 74
1.2 List of Figures
Figure 1: (a) Osteolytic lesions; (b) Osteoblastic lesion 8
Figure 2: Mechanism of Tumor Metastasis to Bone 9
Figure 3: Prevalence of Skeletal-Related Events in Patients with Metastatic Bone Disease not Treated with Bisphosphonates 10
Figure 4: Diagnosis of Bone Metastases 12
Figure 5: Algorithm for Imaging for Cancer Patients in the US 13
Figure 6: Bone Metastases Therapeutics Market, Global, Revenue ($m), 2005–2010 17
Figure 7: Bone Metastases Therapeutics Market, Global, Forecast ($m), 2010–2017 18
Figure 8: Bone Metastases Therapeutics Market, The US, Revenue ($m), 2005–2010 19
Figure 9: Bone Metastases Therapeutics Market, The US, Forecasts ($m), 2010–2017 20
Figure 10: Bone Metastases Therapeutics Market, France, Revenue ($m), 2005–2010 21
Figure 11: Bone Metastases Therapeutics Market, France, Forecasts ($m), 2010–2017 22
Figure 12: Bone Metastases Therapeutics Market, Germany, Revenue ($m), 2005–2010 23
Figure 13: Bone Metastases Therapeutics Market, Germany, Forecasts ($m), 2010–2017 24
Figure 14: Bone Metastases Therapeutics Market, Italy, Revenue ($m), 2005–2010 25
Figure 15: Bone Metastases Therapeutics Market, Italy, Forecasts ($m), 2010–2017 26
Figure 16: Bone Metastases Therapeutics Market, Spain, Revenue ($m), 2005–2010 27
Figure 17: Bone Metastases Therapeutics Market, Spain, Forecasts ($m), 2010–2017 28
Figure 18: Bone Metastases Therapeutics Market, The UK, Revenue ($m), 2005–2010 29
Figure 19: Bone Metastases Therapeutics Market, The UK, Forecasts ($m), 2010–2017 30
Figure 20: Bone Metastases Therapeutics Market, Japan, Revenue ($m), 2005–2010 31
Figure 21: Bone Metastases Therapeutics Market, Japan, Forecasts ($m), 2010–2017 32
Figure 22: Opportunity and Unmet Need in the Bone Metastases Therapeutics Market, 2010 34
Figure 23: Bone Metastases Therapeutics – Strategic Competitor Assessment, 2010 36
Figure 24: Bone Metastases Therapeutics – Pipeline by Phase of Development, 2011 40
Figure 25: Bone Metastases Therapeutics – Technology Trends Analytics Framework, 2011 42
Figure 26: Bone Metastases Therapeutics – Technology Trends Analytics Framework – Description, 2011 42
Figure 27: Bone Metastases Therapeutics – Pipeline by Mechanism of Action, 2010 43
Figure 28: Bone Metastases Therapeutics – Clinical Trials by Country, 2011 47
Figure 29: Bone Metastases Therapeutics - Clinical Trials by Phase, 2011 48
Figure 30: Bone Metastases Therapeutics - Clinical Trials by Status, 2011 49
Figure 31: Bone Metastases Therapeutics - Clinical Trials by Overall Sponsors, 2011 50
Figure 32: Bone Metastases Therapeutics - Clinical Trials by Prominent Sponsors, 2011 51
Figure 33: Bone Metastases Therapeutics - Top Companies Participating in Clinical Trials, 2011 52
Figure 34: Bone Metastases Therapeutics Market, Drivers and Restraints, 2011 53
Figure 35: Implications for Future Market Competition in Bone Metastases, 2011 54
Figure 36: Bone Metastases Therapeutics – Pipeline by Company, 2011 55
Figure 37: GlobalData Market Forecasting Model 81
Companies Mentioned
Novartis AG
Amgen Inc.
Bayer AG
Algeta ASA
Merrion Pharmaceuticals Plc
To order this report:
Drug Discovery and Development Industry: Bone Metastases Therapeutics - Pipeline Assessment and Market Forecasts to 2017
Drug Discovery and Development Business News
Check our Industry Analysis and Insights
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article